<DOC>
	<DOC>NCT00126399</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of 40 mg doxycycline controlled-release capsules administered once daily for the treatment of rosacea compared with a placebo.</brief_summary>
	<brief_title>A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Main Healthy patients with rosacea Males and females ≥18 years of age 10 to 40 papules and pustules and ≤2 nodules Score of 2 to 4 on the IGA Presence of telangiectasia Moderate to severe erythema Main Use of topical acne treatments or topical or systemic antibiotics Use of systemic retinoids within 90 days of baseline Use of an investigational drug within 90 days of baseline Pregnant or nursing women Women of childbearing potential not using an adequate form of contraception Change in method of contraception within 4 months of baseline Known hypersensitivity to tetracyclines Surgeries that bypass or exclude the duodenum or achlorhydria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>rosacea</keyword>
	<keyword>acne rosacea</keyword>
</DOC>